Ghent start-up Nuclivision uses AI-driven imaging to make PET scans safer
Belgian medtech start-up Nuclivision has developed a significant innovation in nuclear medicine: Nuclarity. This AI-powered software platform reduces radiation exposure during PET scans.
By applying advanced deep learning techniques, Nuclarity produces high-quality medical images using less radioactive tracer and shorter scan times, in a breakthrough that improves both patient safety and clinical efficiency.
PET scans are a vital diagnostic tool for identifying cancer, inflammation and neurodegenerative diseases. However, their reliance on radioactive substances raises health and cost concerns. Nuclivision addresses these issues by enhancing image quality through AI, enabling lower doses to be used without compromising diagnostic value.
This article is part of a series highlighting innovative initiatives in Flanders. Throughout the summer, Belga English takes a closer look at emerging companies that are reshaping key sectors.
Growing demand
Founded in late 2022 by engineers Maarten Larmuseau, Tomas Brants and Simon DeKeyser, the Ghent-based company works closely with Belgian nuclear medicine and medical imaging specialists.
Their goal is to meet the growing clinical demand for faster and safer diagnostic tools, especially for illnesses that require frequent or early-stage imaging, such as cancer and Alzheimer’s disease.
"Because the Belgian market is small, we have focused on scaling up internationally from the outset"
Nuclivision has already conducted pilot tests in hospitals in Belgium, France and the Netherlands. The technology recently obtained CE certification, enabling its commercial rollout across Europe. “Because the Belgian market is small, we have focused on scaling up internationally from the outset,” Larmuseau told Trends.
This European expansion is being supported by a recent 5 million euros funding round led by several partners including imec.istart, which was launched in 2011 as one of Europe’s first startup accelerators.
Accelerator support
Nuclivision previously raised 400,000 euros in pre-seed capital and received support from accelerator programmes. Public support also came from VLAIO, the central contact point of the Flemish government for entrepreneurs. It promotes innovation, supports businesses and fosters a favourable entrepreneurial climate.
Rapid advances in nuclear medicine are being driven by theranostics, which uses radioactive compounds for both diagnosis and treatment.
In this field, Nuclivision is emerging as a frontrunner in AI-powered medical imaging. The start-up's Nuclarity platform offers hospitals a scalable solution for handling rising scan volumes, enhancing patient safety and reducing healthcare costs.
#FlandersNewsService | © Nuclivision
Related news
